Fact sheet

As the number of people accessing life-saving drugs for HIV has risen, there has been an increasing sense that the end of AIDS was near. But for children and adolescents, the situation remains grave.

Reaching unreachable population: multi-collaboration framework to improve young key population access towards HIV-related services in demonstration site of Bandung, Indonesia.

In response to a longstanding demand for a heat-stable and easy to administer formulation of ritonavir boosted lopinavir (LPV/r) for infants and young children, a new formulation in pellet form is now available.

This fact sheet provides simplified information to facilitate proper dosing and administration of lopinavir and ritonavir 40mg/10mg oral pellets.

In 2014, only 50% of all HIV-exposed infants were tested by the second month of age. Innovative approaches such as use of assays at the point-of care and adding virological testing at birth could speed up identification and ART initiation. Operational research to fully inform how to implement such innovations remains critical.

Despite this significant progress, the number of children becoming newly infected with HIV remains unacceptably high. About 150,000 [110,000–190,000] children became infected with HIV in 2015, down from 490,000 [430,000–560,000] in 2000.

This document discusses the following: general messages about early childhood development, programming messages, nutrition, protection,  early & lifelong learning,  health, parenting, advocacy messages, and key facts about the developing brain. The messages presented in this note were generated from a Neuroscience Symposium organized by UNICEF on April 16, 2014, where 16 leading international scientists from different fields of neuroscience presented their latest evidence on the influences of experience and environment on child brain development.

Monitoring of individuals on ART is important to ensure treatment efficacy and improved health outcomes. Updated WHO Consolidated ARV Guidelines will be available in December 2015 and include recommendations on routine monitoring and the diagnosis of treatment failure.

WHO recommends initiation of ART for all people living with HIV at any CD4 cell count fixed dose combinations (FDCs) containing TDF/XTC/EFV remain the preferred first line regimen for adults, adolescents and older children For the first time, DTG and EFV400 have been included as alternative first line regimens for adults and adolescents. DRV/r is an alternative option as part of secondline regimens, along with LPV/r and ATV/r.